Taysha Gene Therapies prices $200M public stock offering Jun 24, 2026 10:33PM
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants Jun 24, 2026 10:33PM
Taysha Gene Therapies launches $200M stock and warrant offering Jun 24, 2026 04:01PM
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Jun 24, 2026 04:01PM
Taysha Gene Therapies (TSHA) Reiterated at Overweight by Cantor Fitzgerald on Phase 1/2 Data Mar 25, 2026 07:22AM


Nov 14, 2025 07:26AM Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA)
Oct 17, 2025 07:15AM Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA): Says it's Undervalued
Sep 22, 2025 07:19AM Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA)
Jun 13, 2025 07:11AM Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA)
Jun 12, 2025 07:24AM Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA)
May 29, 2025 08:01AM Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA)
Apr 28, 2025 07:17AM Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA)
Jun 14, 2021 06:48AM Companies with NDRs 6/14